when do we switch to digital- Top Knowledge graph

President of Japan Life Insurance: For some time, we have been hoping to have a company that can become the core business of the United States, the world's largest life insurance market.China Minerals and Guangxi Iron and Steel have established mining technology companies. The enterprise search APP shows that recently, China National Mining Chain (Guangxi) Mining Technology Co., Ltd. was established, with Ji Wendong as the legal representative and a registered capital of 90 million yuan. Its business scope includes mineral washing and processing, metal ore sales and metal material sales. Enterprise survey shows that the company is jointly owned by China Mineral's China Mineral Resources Group International Supply Chain Co., Ltd. and Guangxi Iron and Steel Group Co., Ltd.Yushi Technology: There is no factual basis for the company to be included in the "entity list". At present, the production and operation are normal. Yushi Technology issued a statement today: On December 10, 2024 (Beijing time), the Bureau of Industry and Security of the US Department of Commerce issued relevant announcements to include companies such as Yushi Technology in the entity list. There is no factual basis for this decision, and the company has never received any investigation and evidence collection work from any official US agency. We call on the US government to re-examine. Yushi Technology is an independent private enterprise. As a global provider of AloT products, solutions and full-stack capabilities, Yushi Technology has always adhered to the internationally accepted business ethics and compliance management concept since its establishment 13 years ago, abided by the duties of commercial companies and strictly abided by the laws and regulations of the countries where it operates. At present, the company's production and operation are normal, and this incident has no significant adverse impact on the company's operation. We have the ability to ensure continuous and stable product supply and high-quality technical support for global customers.

In 2024, the rating of brokerage investment banking business is nearing the end, and the results of 96 brokers will be released. The reporter was informed that the quality evaluation of brokerage investment banking business in 2024 is nearing the end, and the evaluation scores of investment banking business quality of 96 participating brokers in 2024 have been distributed to companies. After the brokers confirm, the association will start the formal scoring work. In September this year, the China Securities Association launched the quality evaluation of brokerage investment banking business in 2024, and initially determined the participating brokerage and investment banking projects. According to the preliminary statistics, about 68 brokers are expected to get extra points for supporting high-level science and technology in investment banking. (Cailian)State Railway Administration: From January to November, the national railway passenger volume reached a record high, and the State Railway Administration announced that from January to November, the national railway passenger volume reached a record high. From January to November, the number of railway passengers sent nationwide reached 4.015 billion, up 12.6% year-on-year, and the annual number of passengers sent exceeded 4 billion for the first time, reaching a record high. Passenger turnover reached 1,484.061 billion person-kilometers, a year-on-year increase of 7.8%. In the month of November, the number of railway passengers sent nationwide was 304 million, up 8.8% year-on-year; Passenger turnover reached 98.135 billion person-kilometers, a year-on-year increase of 2.5%. The volume of freight delivery has increased steadily. From January to November, the national railway freight volume was 4.715 billion tons, a year-on-year increase of 2.5%. In November, the national railway freight volume was 455 million tons, a year-on-year increase of 6.4%; The freight turnover was 324.521 billion tons kilometers, up 2.4% year-on-year.Survey by Monetary Authority of Singapore: Economists have lowered Singapore's non-oil domestic export growth forecast from 3.0% to 1.0% in 2024.

Yongtai Bio-product, a new open-source shareholding company, was recognized by CDE for breakthrough therapy. On December 11th, official website, China National Medical Products Administration Drug Evaluation Center (CDE), recently announced that the anti-CD19 single-chain antibody chimeric antigen receptor T cell injection (CAR-T-19 cell injection for short) developed by Yongtai Bio-B (06978.HK) was successfully included in the list of breakthrough therapy varieties by CDE, and the indication was recurrence under 25 years old/.Academician Qiao Jie, Executive Vice President of Peking University, and his party visited Sunflower Pharmaceutical Group. On December 9th, Academician Qiao Jie, Executive Vice President of Peking University, and his party visited the headquarters of Sunflower Pharmaceutical Group for investigation and exchange. At the symposium, Tan Lei, general manager of the strategic management department of Sunflower Pharmaceutical Group, gave a detailed report on the promotion plan of the project "Peking University Medical-Sunflower Pharmaceutical Group Joint Laboratory of Bacterial Enzyme and Innovative Drugs". Sunflower Pharmaceutical Group will join hands with Peking University Medical Center, and the teams of the two sides will cooperate in depth to jointly develop new drugs based on the active substances of traditional Chinese medicine and the discovered important disease targets, promote the transformation of scientific research achievements, deepen the advantageous fields of biotechnology, and help improve the scientific research and innovation ability and technology development level. During the talks, the two sides also conducted in-depth exchanges and discussions on a number of contents.Yongtai Bio-product, a new open-source shareholding company, was recognized by CDE for breakthrough therapy. On December 11th, official website, China National Medical Products Administration Drug Evaluation Center (CDE), recently announced that the anti-CD19 single-chain antibody chimeric antigen receptor T cell injection (CAR-T-19 cell injection for short) developed by Yongtai Bio-B (06978.HK) was successfully included in the list of breakthrough therapy varieties by CDE, and the indication was recurrence under 25 years old/.